June 15, 2020

IBRI IN THE NEWS: Biosciences Institute Develops Diagnosis Technologies

INDIANAPOLIS - The Indiana Biosciences Research Institute in Indianapolis has completed development of two technologies it says could diagnose diseases faster and with more accuracy. The IBRI says its BioMEMs...

June 11, 2020

IBRI Develops Technologies that Help to Diagnose Diseases Faster, More Accurately

INDIANAPOLIS, IND. - The Indiana Biosciences Research Institute (IBRI), a leading independent, industry-inspired applied research institute, is pleased to announce that it has completed development of two technologies – BioMEMs...

June 09, 2020

IBRI and TBH Creative Win Gold Aster Award

We were pleased to partner with TBH Creative to move our 2018 Annual Report from print to online. TBH Creative took the PDF and transformed it into its own microsite...

June 03, 2020

IBRI RESEARCH PUBLISHED: Pre-clinical Evaluation of TYK2 Inhibitors for Human Beta Cell Protection in Type 1 Diabetes

Abstract: Aims: Type 1 diabetes (T1D) is a chronic autoimmune disease leading to progressive loss of pancreatic beta cells. Interferon (IFN)-α plays a critical role in the crosstalk between...

May 29, 2020

IBRI IN THE NEWS: Pushing Hard for a COVID-19 Vaccine

The race is on. Around the world, more than 80 vaccine projects are under development by pharmaceutical companies and university research laboratories scrambling to find a way to slow...

May 26, 2020

New Research Identifies Two Classes of Drugs that Could be Re-purposed for the Early Treatment of T1D

INDIANAPOLIS - Researchers from the Indiana Biosciences Research Institute (IBRI), a leading independent, industry-inspired applied research institute, and Université Libre de Bruxelles (ULB) Center for Diabetes Research, identified two classes...

May 13, 2020

IBRI RESEARCH PUBLISHED: Pancreatic ß-cells in Type 1 and Type 2 Diabetes Mellitus: Different Pathways to Failure

Abstract: Loss of functional β-cell mass is the key mechanism leading to the two main forms of diabetes mellitus — type 1 diabetes mellitus (T1DM) and type 2 diabetes...

April 21, 2020

IBRI RESEARCH PUBLISHED: SUMOylation, a multifaceted regulatory mechanism in the pancreatic beta cells

Abstract SUMOylation is an evolutionarily conserved post-translational modification (PTM) that regulates protein subcellular localization, stability, conformation, transcription and enzymatic activity. Recent studies indicate that SUMOylation plays a key role...

April 16, 2020

IBRI IN THE NEWS: IBRI Names Scientific Director

INDIANAPOLIS - The Indiana Biosciences Research Institute has named Investigator Decio Eizirik as Scientific Director of the IBRI Diabetes Center. Eizirik will focus on recruiting early career investigators and defining...

April 15, 2020

IBRI Names Decio Eizirik Scientific Director of its IBRI Diabetes Center

INDIANAPOLIS, IND. – The Indiana Biosciences Research Institute (IBRI) is pleased to announce that it has named Investigator Decio Eizirik, MD, PhD, Scientific Director of its IBRI Diabetes Center (IDC)....

First 1 2 3 4 5  ... Last 
2019 Annual Report cover

The IBRI 2019 Annual Report is now available. The report theme is “Catalyze, Complement, Connect,” which correlates with the IBRI's goals to seek solutions for health problems, enhance the Indiana life sciences ecosystem, and expedite solutions for the most pressing health issues.